<DOC>
	<DOCNO>NCT02888197</DOCNO>
	<brief_summary>Non-interventional extension study investigate VVC recurrence candida colonization follow P2 acute VVC study</brief_summary>
	<brief_title>Non-Interventional Extension Investigate Recurrence Vulvovaginal Candidiasis Candida Colonization</brief_title>
	<detailed_description>Following completion Phase 2 , multicenter , randomize , active-controlled study safety tolerability two formulation CD101 compare fluconazole treatment moderate severe episode acute vulvovaginal candidiasis ( NCT07299432 ) , subject without recurrence VVC follow additional 90 day +/- 14 day assess candida colonization recurrence VVC .</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Vaginitis</mesh_term>
	<mesh_term>Candidiasis , Vulvovaginal</mesh_term>
	<criteria>Enrollment complete primary study Day 28 visit . Received least one dose study drug primary study Able give write informed consent prior completion primary study Received systemic topical vaginal nonstudy antifungal therapy time primary study Diagnosed bacterial vaginosis , trichomonas , gonorrhea , chlamydia , active herpes point primary study The Principal Investigator considers subject participate study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>